Security
Faeth Therapeutics, Inc. Common Stock · FTH
FTHNASDAQCommon stockCurrentCIK 1829802Updated Oct 28, 2026
Name history
Sensei Biotherapeutics, Inc. · through Jun 16, 2026
FTH price & chart
Loading TradingView…
NASDAQ:FTH on TradingView ↗About the company
Faeth Therapeutics, Inc. (Nasdaq: FTH) is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. The Company’s lead program is PIKTOR, an investigational all-oral combination of serabelisib and sapanisertib in development for endometrial and breast cancer. Faeth was co-founded in 2019 by Anand Parikh and Oliver Maddocks, Ph. D., together with scientific founders Lewis Cantley, Ph. D., the discoverer of the PI3K pathway; Siddhartha Mukherjee, M.D., D.Phil.; Karen Vousden, Ph. D.; Scott Lowe, Ph. D.; and Greg Hannon, Ph. D. The Company intends to use its website as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, please visit www.faeththerapeutics.com and follow the Company on LinkedIn.
In the news
No coverage from other publishers is available.
Recent filings
S-8 filing
Results of Operations and Financial Condition
Items 2.02, 9.01
10-Q filing
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 27,589,000Source | 53,254,000Source | 189,306,000Source | 31,783,000Source | 59,799,000Source | 205,381,000Source | 38,273,000Source | 66,695,000Source | 22,902,000Source | 45,361,000Source | 74,374,000Source | 118,375,000Source |
| Property, Plant and Equipment, NetUSD | 112,000Source | 899,000Source | 44,000Source | 143,000Source | 1,038,000Source | 69,000Source | 159,000Source | 1,065,000Source | 82,000Source | 417,000Source | 1,165,000Source | 2,049,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 10,562,000Source | 19,131,000Source | 26,903,000Source | 12,557,000Source | 11,891,000Source | 152,325,000Source | 9,877,000Source | 10,956,000Source | 8,668,000Source | 9,994,000Source | 13,011,000Source | 17,795,000Source |
| Assets, CurrentUSD | 25,785,000Source | 48,098,000Source | 188,658,000Source | 29,572,000Source | 53,944,000Source | 204,232,000Source | 35,682,000Source | 60,234,000Source | 21,507,000Source | 41,929,000Source | 67,250,000Source | 108,589,000Source |
| Operating Lease, Right-of-Use AssetUSD | 1,668,000Source | 3,206,000Source | 524,000Source | 2,034,000Source | 3,573,000Source | 913,000Source | 2,393,000Source | 3,960,000Source | 1,294,000Source | 2,804,000Source | 4,330,000Source | 5,355,000Source |
| Other Assets, NoncurrentUSD | 18,000Source | 87,000Source | 80,000Source | 24,000Source | 87,000Source | 167,000Source | 24,000Source | 86,000Source | 18,000Source | 48,000Source | 86,000Source | 63,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 4,582,000Source | 7,475,000Source | 9,581,000Source | 4,469,000Source | 7,607,000Source | 14,191,000Source | 6,286,000Source | 8,221,000Source | 4,310,000Source | 6,975,000Source | 9,479,000Source | 14,968,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 0Source | 3,000Source | 2,000Source | 0Source | 3,000Source | 0Source | 3,000Source | 3,000Source | 0Source | 3,000Source | 3,000Source | 3,000Source |
| Retained Earnings (Accumulated Deficit)USD | -278,421,000Source | -254,282,000Source | -469,380,000Source | -273,852,000Source | -247,029,000Source | -453,373,000Source | -268,916,000Source | -239,887,000Source | -283,137,000Source | -262,052,000Source | -231,895,000Source | -197,794,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -3,000Source | 14,000Source | -63,000Source | -11,000Source | -93,000Source | -24,000Source | -6,000Source | -137,000Source | 1,000Source | -13,000Source | -209,000Source | -1,004,000Source |
| Stockholders' Equity Attributable to ParentUSD | 23,007,000Source | 45,779,000Source | 172,958,000Source | 27,314,000Source | 52,192,000Source | -137,286,000Source | 31,987,000Source | 58,474,000Source | 18,592,000Source | 38,386,000Source | 64,895,000Source | 103,407,000Source |
| Additional Paid in Capital, Common StockUSD | 301,431,000Source | 300,044,000Source | 642,399,000Source | 301,177,000Source | 299,311,000Source | 316,111,000Source | 300,906,000Source | 298,495,000Source | 301,728,000Source | 300,448,000Source | 296,996,000Source | 302,202,000Source |
| Liabilities and EquityUSD | 27,589,000Source | 53,254,000Source | 189,306,000Source | 31,783,000Source | 59,799,000Source | 205,381,000Source | 38,273,000Source | 66,695,000Source | 22,902,000Source | 45,361,000Source | 74,374,000Source | 118,375,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 4,436,000Source | 5,441,000Source | 9,580,000Source | 3,873,000Source | 4,949,000Source | 14,190,000Source | 5,229,000Source | 4,992,000Source | 4,251,000Source | 5,448,000Source | 5,643,000Source | 9,066,000Source |
| Operating Lease, Liability, CurrentUSD | 1,682,000Source | 1,603,000Source | 592,000Source | 1,622,000Source | 1,591,000Source | 1,021,000Source | 1,568,000Source | 1,607,000Source | 1,370,000Source | 1,586,000Source | 1,567,000Source | 1,251,000Source |
| Accounts Payable, CurrentUSD | 306,000Source | — | 2,147,000Source | 351,000Source | — | 3,418,000Source | 361,000Source | — | 689,000Source | 244,000Source | — | — |
| Operating Lease, Liability, NoncurrentUSD | 146,000Source | 1,828,000Source | 0Source | 592,000Source | 2,214,000Source | 0Source | 1,022,000Source | 2,590,000Source | 59,000Source | 1,429,000Source | 3,001,000Source | 4,323,000Source |
| Other Liabilities, NoncurrentUSD | — | — | 1,000Source | — | 67,000Source | 1,000Source | — | 68,000Source | — | — | 67,000Source | — |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 1,019,000Source | — | 5,251,000Source | 704,000Source | — | 5,428,000Source | 1,909,000Source | — | 715,000Source | 847,000Source | — | — |
| Goodwill | — | — | —Source | — | — | —Source | — | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -170,236,000Source | -6,864,000Source | -21,085,000Source | -30,157,000Source | -34,101,000Source | -48,588,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 29,000Source | 30,000Source | 122,000Source | 551,000Source | 571,000Source | 614,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 12,898,000Source | 461,000Source | 1,274,000Source | 3,135,000Source | 4,454,000Source | 5,812,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -2,619,000Source | -7,186,000Source | -9,890,000Source | -8,044,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -10,733,000Source | -7,094,000Source | -20,453,000Source | -24,670,000Source | -32,023,000Source | -39,026,000Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -31,436,000Source | 7,191,000Source | 19,772,000Source | 22,440,000Source | 38,412,000Source | 49,949,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 6,000Source | 0Source | 16,000Source | 146,000Source | 180,000Source | 321,000Source |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 0Source | 3,000Source | 3,000Source | 10,000Source | 76,000Source | — |
| Payments for Repurchase of Common StockUSD | — | — | — | — | — | — | — | — | — | — | 10,384,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 185,826,000Source | -214,000Source | -645,000Source | -787,000Source | -11,173,000Source | -287,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 143,657,000Source | -117,000Source | -1,326,000Source | -3,017,000Source | -4,784,000Source | 10,636,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 254,000Source | 733,000Source | 4,483,000Source | 264,000Source | 12,898,000Source | 461,000Source | 1,274,000Source | 3,135,000Source | 4,454,000Source | 5,812,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | -1,000Source | 0Source | — | — | 0Source | 20,000Source | — | — | -302,000Source | — |
| General and Administrative ExpenseUSD | — | — | 2,315,000Source | 3,186,000Source | 9,205,000Source | 2,673,000Source | 19,713,000Source | 3,549,000Source | 11,328,000Source | 13,036,000Source | 18,765,000Source | 19,805,000Source |
| Income Tax Expense (Benefit)USD | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,569,000Source | -7,253,000Source | -16,007,000Source | -4,936,000Source | -170,236,000Source | -6,864,000Source | -21,085,000Source | -30,157,000Source | -34,101,000Source | -48,588,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -4,569,000Source | -7,253,000Source | -16,007,000Source | -4,936,000Source | -170,236,000Source | -6,864,000Source | -21,085,000Source | -30,157,000Source | -34,101,000Source | -48,588,000Source |
| Operating ExpensesUSD | — | — | 4,851,000Source | 7,823,000Source | 18,385,000Source | 5,206,000Source | 170,627,000Source | 7,274,000Source | 22,288,000Source | 32,614,000Source | 37,064,000Source | 50,188,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 0Source | 120,000Source | -41,000Source | -1,000Source | 18,000Source | -4,000Source | -3,000Source | -215,000Source | 36,000Source |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | 1,033,000Source | 0Source | 2,000Source | — | — | 238,000Source |
| Payments to Acquire Businesses, Net of Cash Acquired | — | — | — | — | — | — | —Source | —Source | — | — | — | — |
| Goodwill | — | — | — | — | —Source | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income (Loss)USD | — | — | -4,851,000Source | -7,823,000Source | -18,385,000Source | -5,206,000Source | -170,627,000Source | -7,274,000Source | -22,288,000Source | -32,614,000Source | -37,064,000Source | -50,188,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 0Source | 0Source | 120,000Source | -41,000Source | -1,000Source | 18,000Source | -4,000Source | -3,000Source | -215,000Source | 36,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -21,085,000Source | — | — | — |
| Income Tax Expense (Benefit)USD | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -4,569,000Source | -7,253,000Source | -16,007,000Source | -4,936,000Source | -170,236,000Source | -6,864,000Source | -21,085,000Source | -30,157,000Source | -34,101,000Source | -48,588,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -3.62Source | -5.77Source | -2.84Source | -3.91Source | -131.45Source | -5.45Source | -16.72Source | -1.2Source | -1.22Source | -1.58Source |
| Earnings Per Share, DilutedUSD per share | — | — | -3.62Source | -5.77Source | -2.84Source | -3.91Source | -131.45Source | -5.45Source | -16.72Source | -1.2Source | -1.22Source | -1.58Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 1,261,290Source | 1,257,299Source | 5,643,222Source | 1,260,867Source | 1,295,052Source | 1,259,531Source | 1,260,772Source | 25,117,238Source | 27,952,857Source | 30,703,295Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 1,261,290Source | 1,257,299Source | 5,643,222Source | 1,260,867Source | 1,295,052Source | 1,259,531Source | 1,260,772Source | 25,117,238Source | 27,952,857Source | 30,703,295Source |
| Additional Financial Items | ||||||||||||
| General and Administrative ExpenseUSD | — | — | 2,315,000Source | 3,186,000Source | 9,205,000Source | 2,673,000Source | 19,713,000Source | 3,549,000Source | 11,328,000Source | 13,036,000Source | 18,765,000Source | 19,805,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -21,085,000Source | — | — | — |
| Interest ExpenseUSD | — | — | 6,000Source | 21,000Source | — | 10,000Source | — | 13,000Source | 32,000Source | 90,000Source | 144,000Source | 219,000Source |
| Investment Income, NetUSD | — | — | 289,000Source | 591,000Source | 2,258,000Source | 311,000Source | 392,000Source | 392,000Source | 1,239,000Source | 2,550,000Source | 3,624,000Source | 1,783,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | -4,569,000Source | -7,253,000Source | -16,007,000Source | -4,936,000Source | -170,236,000Source | -6,864,000Source | -21,085,000Source | -30,157,000Source | -34,101,000Source | -48,588,000Source |
| Operating ExpensesUSD | — | — | 4,851,000Source | 7,823,000Source | 18,385,000Source | 5,206,000Source | 170,627,000Source | 7,274,000Source | 22,288,000Source | 32,614,000Source | 37,064,000Source | 50,188,000Source |
Offerings
Registration 333-296894
Registration 333-295362
Filing attachments
snse-ex99_1.htm · S-8 · 2026-11-03
Exhibit 99.1 Faeth Therapeutics, Inc. 2026 Equity Incentive Plan Adopted by the Board of Directors: April 10, 2026Approved by the Stockholders: JUNE 10, 2026 1. General. (a) Successor to Prior Plan. The Plan is the successor to the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; and (ii) all outstanding awards granted under the Prior Plan will remain subject to the terms of the Prior Plan. All Awards granted under this Plan will be subje…
Read attachment ↗snse-ex99_2.htm · S-8 · 2026-11-03
Exhibit 99.2 Faeth Therapeutics, Inc. 2026 Employee Stock Purchase Plan Adopted by the Board of Directors: April 10, 2026 Approved by the Stockholders: JUNE 10, 2026 1. General; Purpose. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to grant a series of Purchase Rights to Eligible Employees under an Employee Stock Purchase Plan. In additi…
Read attachment ↗d144290dex991.htm · 8-K · 2026-11-03
Exhibit 99.1 Faeth Therapeutics Reports Third Quarter 2026 Financial Results and Operational Updates Topline results from the Phase 2 PIK-201 trial in endometrial cancer expected by year-end FDA granted Fast Track designation to PIKTOR plus paclitaxel in biomarker-selected advanced endometrial cancer Presented preclinical data on PIKTOR in HR+/HER2- breast cancer models at ESMO 2026 AUSTIN, Texas - (BUSINESS WIRE) - November 3, 2026 - Faeth Therapeutics (Nasdaq: FTH), a clinical-s…
Read attachment ↗tm2621614d2_ex99-1.htm · SCHEDULE 13G/A · 2026-08-14
Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of th…
Read attachment ↗d168633dex991.htm · 8-K · 2026-08-04
EX-99.1 2 d168633dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 Faeth Therapeutics Reports Second Quarter 2026 Financial Results and Operational Updates - Topline results from the Phase 2 PIK-201 trial in endometrial cancer on track for year-end - - First patient dosed in the Phase 1b/2 PIK-101 trial in HR+ breast cancer - - Company changed name to Faeth Therapeutics, Inc. on June 15, 2026; common stock began trading under the ticker symbol “FTH” on June 16, 2026 - AUSTIN, Texas - (BUSINESS W…
Read attachment ↗d837676dex42.htm · S-3ASR · 2026-06-18
Exhibit 4.2 FAETH THERAPEUTICS, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of [●], 20__ Debt Securities T ABLE O F C ONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 …
Read attachment ↗